Cancer

Luminal A and B breast cancers, collectively known as hormone receptor–positive (HR+) disease, represent the most

In this discussion, we investigate the optimal cell source for constructing 3D adipose models, predicated on

HER2-positive breast cancer represents about one quarter of breast malignancies and is driven by amplification of

Triple-negative breast cancer (TNBC) is a distinct pathological subtype defined by the absence of estrogen receptor

Breast cancer remains the most common malignancy in women worldwide, and progress in treatment increasingly depends

Breast cancer is the second cancer-related cause of death in women worldwide, therefore it is no

Introduction Microphysiological systems (MPS) are fast becoming a cornerstone of FDA-aligned non-clinical strategy, especially when paired

Introduction Organoid and artificial intelligence approaches are central to the FDA’s roadmap for reducing animal use

Introduction Adipose tissue-breast cancer crosstalk is emerging as a key driver of tumor initiation, progression, and